News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
269,065 Results
Type
Article (14303)
Company Profile (281)
Press Release (254481)
Multimedia
Podcasts (49)
Webinars (7)
Section
Business (79601)
Career Advice (153)
Deals (13237)
Drug Delivery (35)
Drug Development (50488)
Employer Resources (31)
FDA (5730)
Job Trends (5144)
News (144549)
Policy (10042)
Tag
Academia (916)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21716)
ALS (69)
Alzheimer's disease (851)
Antibody-drug conjugate (ADC) (108)
Approvals (5756)
Artificial intelligence (133)
Autoimmune disease (19)
Automation (5)
Bankruptcy (105)
Best Places to Work (4563)
BIOSECURE Act (6)
Biosimilars (44)
Biotechnology (232)
Bladder cancer (59)
Brain cancer (20)
Breast cancer (161)
Cancer (1522)
Cardiovascular disease (121)
Career advice (134)
Career pathing (2)
CAR-T (123)
Cell therapy (340)
Cervical cancer (9)
Clinical research (41190)
Collaboration (559)
Compensation (277)
Complete response letters (13)
COVID-19 (1036)
CRISPR (44)
C-suite (172)
Cystic fibrosis (78)
Data (1611)
Denatured (11)
Depression (32)
Diabetes (142)
Diagnostics (1304)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (29)
Drug shortages (3)
Duchenne muscular dystrophy (91)
Earnings (30120)
Editorial (19)
Employer branding (4)
Employer resources (29)
Events (48803)
Executive appointments (475)
FDA (6502)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (511)
Gene editing (102)
Generative AI (10)
Gene therapy (264)
GLP-1 (372)
Government (1087)
Grass and pollen (2)
Guidances (69)
Healthcare (6596)
Huntington's disease (23)
IgA nephropathy (25)
Immunology and inflammation (99)
Indications (20)
Infectious disease (1103)
Inflammatory bowel disease (120)
Inflation Reduction Act (8)
Influenza (20)
Intellectual property (68)
Interviews (18)
IPO (7281)
IRA (11)
Job creations (865)
Job search strategy (127)
Kidney cancer (7)
Labor market (8)
Layoffs (215)
Leadership (3)
Legal (1386)
Liver cancer (34)
Lung cancer (207)
Lymphoma (103)
Machine learning (5)
Management (7)
Manufacturing (147)
MASH (63)
Medical device (2604)
Medtech (2605)
Mergers & acquisitions (6296)
Metabolic disorders (406)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (73)
Neuropsychiatric disorders (25)
Neuroscience (1276)
NextGen: Class of 2025 (2018)
Non-profit (852)
Now hiring (22)
Obesity (197)
Opinion (103)
Ovarian cancer (67)
Pain (45)
Pancreatic cancer (60)
Parkinson's disease (123)
Partnered (8)
Patents (136)
Patient recruitment (82)
Peanut (35)
People (25697)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14549)
Phase II (19162)
Phase III (12108)
Pipeline (934)
Policy (49)
Postmarket research (852)
Preclinical (6161)
Press Release (30)
Prostate cancer (64)
Psychedelics (35)
Radiopharmaceuticals (214)
Rare diseases (298)
Real estate (1420)
Recruiting (12)
Regulatory (8684)
Reports (16)
Research institute (939)
Resumes & cover letters (17)
Rett syndrome (5)
RNA editing (5)
RSV (10)
Schizophrenia (64)
Series A (99)
Series B (66)
Service/supplier (1)
Sickle cell disease (41)
Special edition (12)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1980)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (12)
The Weekly (37)
Vaccines (217)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (129)
Last 7 days (605)
Last 30 days (1831)
Last 365 days (19391)
2025 (7055)
2024 (20557)
2023 (22418)
2022 (26834)
2021 (27814)
2020 (23364)
2019 (16226)
2018 (11750)
2017 (13750)
2016 (11847)
2015 (14358)
2014 (10407)
2013 (7507)
2012 (7538)
2011 (7624)
2010 (7437)
Location
Africa (148)
Alabama (43)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17373)
Australia (2943)
California (4065)
Canada (1175)
China (377)
Colorado (153)
Connecticut (155)
Delaware (110)
Europe (37394)
Florida (498)
Georgia (124)
Idaho (16)
Illinois (239)
India (10)
Indiana (94)
Iowa (2)
Japan (78)
Kansas (63)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (493)
Massachusetts (3241)
Michigan (73)
Minnesota (152)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (1011)
New Mexico (12)
New York (1089)
North Carolina (570)
North Dakota (5)
Northern California (1815)
Ohio (115)
Oklahoma (9)
Oregon (21)
Pennsylvania (768)
Puerto Rico (6)
Rhode Island (19)
South America (208)
South Carolina (5)
Southern California (1558)
Tennessee (25)
Texas (473)
United States (13893)
Utah (56)
Virginia (83)
Washington D.C. (31)
Washington State (362)
Wisconsin (16)
269,065 Results for "artemis therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD
March 4, 2025
·
10 min read
Press Releases
Persephone Biosciences Announces First Subject Enrolled in ARTEMIS Clinical Trial of New Infant Synbiotic
January 23, 2025
·
4 min read
Drug Development
Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy
Omeros Corporation (Nasdaq: OMER) today provided an update regarding the interim analysis outcome in ARTEMIS-IGAN, the Company’s Phase 3 trial evaluating narsoplimab for the treatment of immunoglobulin A (IgA) nephropathy.
October 16, 2023
·
5 min read
Drug Development
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells
September 27, 2024
·
5 min read
The Royal Marsden set to be the first center in the world to implement online adaptive radiation therapy utilizing ARTemis from RaySearch
RaySearch Laboratories AB is proud to announce that The Royal Marsden NHS Foundation Trust, a specialist cancer center in the UK, will be the first in the world to implement online adaptive radiation therapy with RaySearch’s treatment planning system RayStation®* and oncology information system RayCare®* - including the new ARTemis* OART solution under development - in combination with the Radixact® Treatment Delivery System from Accuray.
February 8, 2024
·
3 min read
Drug Development
Eureka Therapeutics Advances ARYA-3 Clinical Trial to Phase II for Treatment of Liver Cancer Using GPC3-Targeting ARTEMIS® T-cell Therapy
Eureka Therapeutics, Inc. today announced the advancement of its ARYA-3 clinical trial to Phase II ( NCT04864054 ).
March 18, 2024
·
2 min read
Business
Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS® T Cell Therapy for Neuroblastoma
Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS ® T Cell Therapy for Neuroblastoma.
October 18, 2022
·
2 min read
Pharm Country
Trevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes Study
Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced new topline OLINVYK data from the ARTEMIS study.
June 26, 2023
·
16 min read
Drug Development
Prometheus Biosciences Completes Enrollment of the ARTEMIS-UC Cohort 1 Phase 2 Study in Ulcerative Colitis
Prometheus Biosciences, Inc. today announced the completion of enrollment for Cohort 1 of the ARTEMIS-UC global Phase 2 study of PRA023 in ulcerative colitis (UC).
July 18, 2022
·
6 min read
Biotech Beach
Prometheus Biosciences Provides Enrollment Update in APOLLO-CD and ARTEMIS-UC Global Phase 2 Studies
Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced an enrollment update on the APOLLO-CD and ARTEMIS-UC trials.
June 8, 2022
·
8 min read
1 of 26,907
Next
